A Phase I, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Intravenous ETX2514 Administered in Healthy Subjects

Trial Profile

A Phase I, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Intravenous ETX2514 Administered in Healthy Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 09 Oct 2017

At a glance

  • Drugs ETX 2514 (Primary) ; Sulbactam/ETX 2514 (Primary) ; Imipenem/cilastatin; Sulbactam
  • Indications Acinetobacter infections
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Entasis Therapeutics
  • Most Recent Events

    • 09 Oct 2017 According to an Entasis Therapeutics media release, data were presented at IDWeek 2017.
    • 28 Sep 2017 According to an Entasis Therapeutics media release, data will be presented at IDWeek 2017.
    • 30 Jun 2017 According to an Entasis Therapeutics media release, results from this trial is expected in late 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top